Development and Application of an Artificial Intelligence-driven Accurate Identification Model for Gastric Cancer Lymph Node Metastasis

Last updated: August 1, 2024
Sponsor: Hebei Medical University
Overall Status: Active - Recruiting

Phase

N/A

Condition

Digestive System Neoplasms

Gastric Cancer

Stomach Cancer

Treatment

AI-Driven Identification Model for Gastric Cancer Lymph Node Metastasis (AID-GLNM)

Clinical Study ID

NCT06534814
FUTURE08
  • Ages > 18
  • All Genders

Study Summary

The clinical trial titled "Development and Application of an Artificial Intelligence-Driven Accurate Identification Model for Gastric Cancer Lymph Node Metastasis" aims to enhance the detection and treatment of gastric cancer through the utilization of cutting-edge artificial intelligence (AI) technology. This study will develop an AI-driven model designed to accurately identify lymph node metastasis in patients with gastric cancer, which is crucial for staging the disease and planning effective treatment strategies.

The trial will involve a multidisciplinary team of oncologists, radiologists, data scientists, and AI experts who will collaborate to create a robust and precise identification system. Participants will undergo standard diagnostic procedures, and the AI model will analyze imaging and pathological data to predict lymph node involvement.

By comparing the AI model's predictions with traditional diagnostic methods, the study seeks to validate the model's accuracy and efficiency. This approach is expected to improve early detection rates, reduce diagnostic errors, and ultimately lead to better clinical outcomes for patients with gastric cancer. The successful implementation of this AI-driven model could revolutionize the current standards of care and serve as a blueprint for integrating AI technologies in other cancer diagnoses and treatments.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Diagnosis of Gastric Cancer: Confirmed diagnosis of gastric cancer, either newlydiagnosed or recurrent.

  2. Lymph Node Involvement: Suspected or confirmed involvement of lymph nodes, asindicated by imaging studies or pathology reports.

  3. Age: Patients aged 18 years or older.

  4. Performance Status: An Eastern Cooperative Oncology Group (ECOG) performance statusof 0 to 2, indicating a functional status that allows participation in the study.

  5. Informed Consent: Ability to provide written informed consent to participate in thestudy.

Exclusion

Exclusion Criteria:

  1. Pregnancy or Lactation: Pregnant or lactating women, due to potential risks to thefetus or infant.

  2. Severe Comorbid Conditions: Presence of severe comorbid medical conditions thatcould interfere with the study or pose additional risks.

  3. Previous AI-Driven Diagnostic Intervention: Prior use of any AI-driven diagnosticmodels specifically for gastric cancer lymph node metastasis.

  4. Inability to Comply: Inability or unwillingness to comply with study procedures,including follow-up visits and data collection.

  5. Mental or Cognitive Impairment: Conditions that impair the ability to provideinformed consent or participate effectively in the study.

Study Design

Total Participants: 300
Treatment Group(s): 1
Primary Treatment: AI-Driven Identification Model for Gastric Cancer Lymph Node Metastasis (AID-GLNM)
Phase:
Study Start date:
July 01, 2024
Estimated Completion Date:
July 30, 2030

Connect with a study center

  • Department of General Surgery

    Shijiazhuang, Hebei 050011
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.